Loading...
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
PURPOSE: Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is expressed by normal and malign...
Saved in:
| Published in: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Clinical Oncology
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6067798/ https://ncbi.nlm.nih.gov/pubmed/29812997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8084 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|